Search results
Apr 25, 2024 · Unity Biotechnology is a biotech company that develops senolytic drugs to target senescent cells and treat age-related diseases, such as vision loss and cognitive decline. Learn about their science, pipeline, and latest news on their website.
- About Us
WE ASPIRE TO DEVELOP TRANSFORMATIVE MEDICINES TO SLOW, HALT,...
- The Science
UNITY is at the forefront of developing a new class of...
- Pipeline
UNITY’s most advanced drug candidate, UBX1325, is currently...
- Patients
CLINICAL TRIAL ACCESS Thank you for your interest in UNITY...
- Investors & Media
UNITY Biotechnology is developing therapeutics to slow, halt...
- Work with us
THE HEART OF UNITY At UNITY, we foster an inclusive culture...
- Contact Us
285 East Grand Avenue South San Francisco, CA 94080....
- Press Releases
SOUTH SAN FRANCISCO, Calif. , April 23, 2024 (GLOBE...
- About Us
Unity Biotechnology is a biotech company that aims to slow, halt, or reverse diseases of aging, such as diabetic macular edema and age-related neurologic conditions. Learn about their management, board, founders, steering team, advisory team, and company culture.
Mar 15, 2022 · Unity Biotechnology is a biotech company developing therapeutics to target cellular senescence and aging-related biology in ophthalmologic and neurologic diseases. Find stock information, news releases, presentations, and in-the-news articles on its website.
Unity Biotechnology is developing senolytic drugs that target senescent cells and their signaling pathways for ophthalmologic and neurologic diseases. Learn about its lead product candidate, UBX1325, a Bcl-xL inhibitor for diabetic macular edema, and other programs in clinical and preclinical stages.
Unity Biotechnology is a publicly traded American biotechnology company that develops drugs that target senescent cells.
Find the latest Unity Biotechnology, Inc. (UBX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Dec 12, 2023 · UNITY Biotechnology is a biotech company developing senolytic therapies for aging-related diseases. It has dosed the first patients in a Phase 2 trial of UBX1325, a Bcl-xL inhibitor, for diabetic macular edema (DME), a vision-threatening condition.